Next Article in Journal
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
Previous Article in Journal
Left Ventricular Dysfunction and Plasmatic NT-proBNP Are Associated with Adverse Evolution in Respiratory Syncytial Virus Bronchiolitis
Open AccessArticle

HIV Viral Load Estimation Using Hematocrit Corrected Dried Blood Spot Results on a BioMerieux NucliSENS® Platform

1
National TB and HIV/AIDS Programme, Ministry of Health and Child Care, Harare P O Box CY1122 Causeway, 00263, Zimbabwe
2
International Union against Tuberculosis and Lung Disease (The Union), 75006 Paris, France
3
The Union South-East Asia, New Delhi 110016, India
4
Karuna Trust, Bengaluru 560041, India
5
Faculty of Medicine, Université de Parakou, Parakou BP:123, Benin
6
The Union Zimbabwe Office, Harare 00263, Zimbabwe
7
Light-House Trust, Lilongwe 00265, Malawi
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(3), 86; https://doi.org/10.3390/diagnostics9030086
Received: 5 June 2019 / Revised: 17 July 2019 / Accepted: 26 July 2019 / Published: 30 July 2019
While reporting human immunodeficiency virus (HIV) viral load (VL) using dried blood spot (DBS) in the BioMerieux NucliSENS platform, application of the hematocrit correction factor has been suggested. In this cross-sectional study from the National Microbiology Reference Laboratory of Zimbabwe, we assessed whether hematocrit correction (individual and/or mean) in DBS results improved the correlation with plasma VL and prediction of VL non-suppression (≥1000 copies per ml in plasma). Of 517 specimens during August–December 2018, 65(12.6%) had non-suppressed plasma VL results. The hematocrit correction factor ranged from 1.3 to 2.0 with a mean of 1.6, standard deviation (SD: 1.5, 1.7). The intraclass correlation (ICC) for mean (0.859, 95% CI: 0.834, 0.880) and individual (0.809, 95% CI: 0.777, 0.837) hematocrit corrected DBS results were not significantly different. The uncorrected DBS results had a significantly lower ICC (0.640, 95% CI: 0.586, 0.688) when compared to corrected DBS results. There were no significant differences in validity, predictive values, and areas under the receiver operating characteristics curves for all three DBS results when predicting VL non-suppression. To conclude, hematocrit correction of DBS VL results improved agreement with the plasma results but did not improve prediction of VL non-suppression. The results were not significantly different for individual and mean corrected results. View Full-Text
Keywords: viral load; dried blood spot; Antiretroviral therapy (ART) monitoring; human immunodeficiency virus; hematocrit viral load; dried blood spot; Antiretroviral therapy (ART) monitoring; human immunodeficiency virus; hematocrit
Show Figures

Figure 1

MDPI and ACS Style

Nyagupe, C.; Shewade, H.D.; Ade, S.; Timire, C.; Tweya, H.; Vere, N.; Chipuka, S.; Sisya, L.; Gumbo, H.; Ditima, E.; Zinyowera, S. HIV Viral Load Estimation Using Hematocrit Corrected Dried Blood Spot Results on a BioMerieux NucliSENS® Platform. Diagnostics 2019, 9, 86.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop